Addition of fibrates to simvastatin therapy in hyperlipidaemic patients
| Autor: | J.P. Deslypere |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Bezafibrate
Combination therapy biology business.industry Reductase Pharmacology chemistry.chemical_compound chemistry Simvastatin Low-density lipoprotein HMG-CoA reductase medicine European atherosclerosis society biology.protein lipids (amino acids peptides and proteins) medicine.symptom Cardiology and Cardiovascular Medicine Myopathy business medicine.drug |
| Zdroj: | Atherosclerosis. 97:S67-S71 |
| ISSN: | 0021-9150 |
| DOI: | 10.1016/0021-9150(92)90166-e |
| Popis: | A number of new drugs, known as β-hydroxy-β-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, have recently been introduced that are more effective in reducing plasma low density lipoprotein (LDL)-cholesterol levels than existing drugs. In some cases, however, treatment with these inhibitors alone does not reduce LDL to the target levels recommended by the European Atherosclerosis Society. Treatment with a combination of a HMG-CoA reductase inhibitor and either a resin or nicotinic acid has been advocated, but gives rise to gastrointestinal side-effects. While combination therapy with fibrates has been reported to give rise to myopathy, this side-effect appears to be rare. A long-term (30-month) study was therefore initiated to investigate combination therapy with simvastatin and bezafibrate. Forty patients with either familial hypercholesterolaemia or combined hyperlipidaemia were enrolled in the study. At the end of 1 year of monotherapy with simvastatin, 40 mg daily, plasma lipid levels had changed significantly ( P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|